What are the payment terms?

Payment terms include LC, T/T, D/P, PayPal, Western Union, and small-amount payments.

What is the average lead time?

The average lead time is one month for both peak and off-peak seasons.

High Stability and High Water Solubility Feed Additive Red-Bull Vitamin Oral Solution with High Efficency for Animals

Name: High Stability and High Water Solubility Feed Additive Red-Bull Vitamin Oral Solution with High Efficency for Animals
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1973572842

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$1.95-2.20

1,000 Pieces

Sample price:US$2.00/piece.Request sample

Product profile

Customization

Available

Certification

QS, ISO

Shape

Liquid

Type

Vitamin

Function

Vitamin Additives

Specification

1L/bottle

Trademark

Moosun

Origin

China

HS Code

2309901000

Production Capacity

500tons/Month

Key features

High Water Solubility: Prevents water line blockage with high bioavailability and prolonged residence time.

Scientific Nutrition Match: 18 vitamins and amino acids matched according to the gold ratio for optimal efficacy.

Egg Quality Improvement: Increases eggshell strength, reduces breakage, and improves eggshell color.

Poultry Growth Promotion: Enhances growth, feather color, and production performance of poultry.

Immunity Enhancement: Boosts stress resistance, disease resistance, and accelerates recovery.

ISO & QS Certified: Product meets ISO and QS certification standards for quality assurance.

OEM/ODM Services: Customization available with 20 R&D engineers and advanced production equipment.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤10.92h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.